Wuhan-based cell therapy developer iRegene has reached a clinical milestone with the administration of its novel treatment, NouvNeu001, to a patient at Zhongnan Hospital of Wuhan University. The patient’s postoperative condition has been reported as good. In August 2023, NouvNeu001 received approval to be evaluated in a multi-center, open Phase I/II study for middle- to late-stage Parkinson’s disease (PD) in China. As a Category 1 biologic product, it is recognized as the world’s first universal ophthalmic cell therapy product derived from induced pluripotent stem cells (iPSCs) designed to treat PD.
NouvNeu001 leverages chemical induction to achieve high-purity neuronal subtype reconstruction and functional optimization. Post-transplantation, the therapy is capable of forming connections with the body’s existing neurons and enhancing cell secretion functions. This process is expected to further improve the transplanted cells’ impact on existing lesions, leading to comprehensive therapeutic effects for Parkinson’s disease.- Flcube.com
